

Pulmonary Arterial Hypertension (PAH) Market in China 2021

<https://marketpublishers.com/r/P1C1A5A62D83EN.html>

Date: March 2021

Pages: 22

Price: US\$ 450.00 (Single User License)

ID: P1C1A5A62D83EN

Abstracts

The pulmonary arterial hypertension (PAH) market in China in terms of revenue is set to grow by US\$ 787 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 49.6% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for pulmonary arterial hypertension (PAH). The China pulmonary arterial hypertension (PAH) market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

The report has profiled some of the key players of the market such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the pulmonary arterial hypertension (PAH) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China

Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the China pulmonary arterial hypertension (PAH) market

Pinpoint growth sectors and trends for investment

Understand what the future of the pulmonary arterial hypertension (PAH) market in China looks like

Identify the competitive landscape and window of opportunity

Contents

1. MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. MARKET DATA & OUTLOOK

3.1 Market Value

3.2 Market Value Forecast

4. PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET BY REGION

4.1 Central South China

4.2 East China

4.3 North China

4.4 Northeast China

4.5 Northwest China

4.6 Southwest China

5. COMPANY PROFILES

5.1 Actelion Pharmaceuticals Ltd.

5.2 Bayer AG

5.3 Beijing Tide Pharmaceutical Co., Ltd.

5.4 GlaxoSmithKline plc

5.5 United Therapeutics Corporation

6. APPENDIX

6.1 About StrategyHelix

6.2 Disclaimer

I would like to order

Product name: Pulmonary Arterial Hypertension (PAH) Market in China 2021

Product link: <https://marketpublishers.com/r/P1C1A5A62D83EN.html>

Price: US\$ 450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P1C1A5A62D83EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970